Published in Oral Surg Oral Med Oral Pathol Oral Radiol Endod on May 01, 1999
Anesthetic efficacy of a combination of hyaluronidase and lidocaine with epinephrine in inferior alveolar nerve blocks. Anesth Prog (2001) 1.13
Anesthetic efficacy of infiltrations in mandibular anterior teeth. Anesth Prog (2001) 0.94
Anesthetic efficacy of buccal and lingual infiltrations of lidocaine following an inferior alveolar nerve block in mandibular posterior teeth. Anesth Prog (2007) 0.92
Anesthetic efficacy of combinations of 0.5 m mannitol and lidocaine with epinephrine in inferior alveolar nerve blocks: a prospective randomized, single-blind study. Anesth Prog (2011) 0.88
A prospective, randomized, double-blind study of the anesthetic efficacy of sodium bicarbonate buffered 2% lidocaine with 1:100,000 epinephrine in inferior alveolar nerve blocks. Anesth Prog (2010) 0.84
Anesthetic efficacy of lidocaine/meperidine for inferior alveolar nerve blocks. Anesth Prog (2006) 0.83
Design and development of a device for facilitation of Gow-Gates mandibular block and evaluation of its efficacy. Oral Maxillofac Surg (2008) 0.83
Anesthetic efficacy of a combination of 0.5 M mannitol plus 127.2 mg of lidocaine with 50 μg epinephrine in inferior alveolar nerve blocks: a prospective randomized, single-blind study. Anesth Prog (2013) 0.81
Supplemental pulpal anesthesia for mandibular teeth. J Pharm Bioallied Sci (2013) 0.81
Articaine and mepivacaine buccal infiltration in securing mandibular first molar pulp anesthesia following mepivacaine inferior alveolar nerve block: A randomized, double-blind crossover study. Saudi J Anaesth (2015) 0.80
Anesthetic efficacy of an infiltration in mandibular anterior teeth following an inferior alveolar nerve block. Anesth Prog (2002) 0.78
Anesthetic efficacy of a combination of 0.9 M mannitol plus 68.8 mg of lidocaine with 50 μg epinephrine in inferior alveolar nerve blocks: a prospective randomized, single blind study. Anesth Prog (2013) 0.78
Periodontal intraligament injection as alternative to inferior alveolar nerve block--meta-analysis of the literature from 1979 to 2012. Clin Oral Investig (2013) 0.76
Effective anaesthesia of the acutely inflamed pulp: part 1. The acutely inflamed pulp. Br Dent J (2015) 0.75
A Randomized Controlled Study Comparing Efficacy of Classical and Gow-Gates Technique for Providing Anesthesia During Surgical Removal of Impacted Mandibular Third Molar: A Split Mouth Design. J Maxillofac Oral Surg (2016) 0.75
Effect of massage on the efficacy of the mental and incisive nerve block. Anesth Prog (2013) 0.75
Mannitol an adjuvant in local anaesthetic solution: recent concept & changing trends (review). J Clin Diagn Res (2014) 0.75
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest (2004) 4.54
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet (2009) 4.02
Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis (2005) 2.40
Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol (2001) 2.17
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 2.12
Mechanical strength of repairs of the rotator cuff. J Bone Joint Surg Br (1994) 2.12
Hip damage occurs at the zone of femoroacetabular impingement. Clin Orthop Relat Res (2008) 2.06
Protonation states of membrane-embedded carboxylic acid groups in rhodopsin and metarhodopsin II: a Fourier-transform infrared spectroscopy study of site-directed mutants. Proc Natl Acad Sci U S A (1993) 1.97
Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis (2009) 1.89
The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet (2004) 1.79
An evaluation of an electric pulp tester as a measure of analgesia in human vital teeth. J Endod (1987) 1.79
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2000) 1.77
Multidisciplinary management of Hunter syndrome. Pediatrics (2009) 1.76
Effect of systemic penicillin on pain in untreated irreversible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 1.74
Biosynthesis of proteodermatan sulfate in cultured human fibroblasts. J Biol Chem (1984) 1.71
Microinjection and growth of bacteria in the cytosol of mammalian host cells. Proc Natl Acad Sci U S A (2001) 1.71
Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet (2005) 1.67
Treatment of bilateral superior oblique tendon sheath syndrome complicating rheumatoid arthritis. Br J Ophthalmol (1980) 1.62
Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet (2009) 1.61
White matter lesion severity in male and female patients with Fabry disease. Neurology (2005) 1.61
Total hip arthroplasty in young adults after failed triple innominate osteotomy. J Arthroplasty (2001) 1.57
Investigating the microenvironments of inhomogeneous soft materials with multiple particle tracking. Phys Rev E Stat Nonlin Soft Matter Phys (2001) 1.56
Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis (2001) 1.56
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis (2003) 1.52
Distinct phosphatidylinositol 3-kinase lipid products accumulate upon oxidative and osmotic stress and lead to different cellular responses. J Biol Chem (1999) 1.49
Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve (2002) 1.47
Cardiovascular effects of intraosseous injections of 2 percent lidocaine with 1:100,000 epinephrine and 3 percent mepivacaine. J Am Dent Assoc (1999) 1.47
Perception of pain to three different intraoral penetrations of needles. J Am Dent Assoc (1979) 1.40
One environment--different sickness rates. Occup Health (Lond) (1981) 1.38
Horse chestnut seed extract. Lancet (1990) 1.37
An evaluation of volumes and concentrations of lidocaine in human inferior alveolar nerve block. J Endod (1989) 1.36
Anesthetic efficacy of the intraosseous injection after an inferior alveolar nerve block. J Endod (1996) 1.32
Anesthetic efficacy and heart rate effects of the supplemental intraosseous injection of 2% mepivacaine with 1:20,000 levonordefrin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1999) 1.30
Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene. Hum Mutat (1993) 1.29
[Femoroacetabular impingement: trigger for the development of coxarthrosis]. Orthopade (2006) 1.29
Anesthetic efficacy of the supplemental intraosseous injection of 3% mepivacaine in irreversible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1997) 1.29
Ultrastrong coupling of the cyclotron transition of a 2D electron gas to a THz metamaterial. Science (2012) 1.27
Anesthetic efficacy of the supplemental intraosseous injection of 2% lidocaine with 1:100,000 epinephrine in irreversible pulpitis. J Endod (1998) 1.26
Fabry disease: a review of current management strategies. QJM (2010) 1.24
An evaluation of the incisive nerve block and combination inferior alveolar and incisive nerve blocks in mandibular anesthesia. J Endod (1992) 1.21
Free nerve endings in the ligamentum capitis femoris. Acta Orthop Scand (2000) 1.20
Molecular approaches to enteroviral diagnosis in idiopathic cardiomyopathy and myocarditis. J Am Coll Cardiol (1990) 1.19
Randomized study of phentolamine mesylate for reversal of local anesthesia. J Dent Res (2008) 1.18
Stress-related immune suppression: health implications. Brain Behav Immun (1987) 1.18
Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common alpha-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet (1994) 1.18
Developmental motoneuron cell death and neurotrophic factors. Cell Tissue Res (2000) 1.17
Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab (2013) 1.17
An evaluation of 4% prilocaine with 1:200,000 epinephrine and 2% mepivacaine with 1:20,000 levonordefrin compared with 2% lidocaine with:100,000 epinephrine for inferior alveolar nerve block. Anesth Prog (1992) 1.16
Dipole coupling of a double quantum dot to a microwave resonator. Phys Rev Lett (2012) 1.15
Os acetabuli in femoro-acetabular impingement: stress fracture or unfused secondary ossification centre of the acetabular rim? Hip Int (2009) 1.15
Anesthetic efficacy of the intraosseous injection in maxillary and mandibular teeth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1996) 1.15
Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr (1995) 1.14
Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr (2007) 1.14
An evaluation of 4% prilocaine and 3% mepivacaine compared with 2% lidocaine (1:100,000 epinephrine) for inferior alveolar nerve block. J Endod (1993) 1.13
Anesthetic efficacy of a combination of hyaluronidase and lidocaine with epinephrine in inferior alveolar nerve blocks. Anesth Prog (2001) 1.13
Anesthetic efficacy of the intraosseous injection of 2% lidocaine (1:100,000 epinephrine) and 3% mepivacaine in mandibular first molars. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1997) 1.13
Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet (2000) 1.13
Entry point soft tissue damage in antegrade femoral nailing: a cadaver study. J Orthop Trauma (2001) 1.12
The use of ultrasound for guiding needle placement for inferior alveolar nerve blocks. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1999) 1.11
Identification of 31 novel mutations in the N-acetylgalactosamine-6-sulfatase gene reveals excessive allelic heterogeneity among patients with Morquio A syndrome. Hum Mutat (1997) 1.10
Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis (2005) 1.10
Mucopolysaccharidosis type II (Hunter syndrome): mutation "hot spots" in the iduronate-2-sulfatase gene. Am J Hum Genet (1996) 1.09
Hazards in the use of diphencyprone. Br J Dermatol (1997) 1.09
Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet (2005) 1.09
Cartilage damage in femoroacetabular impingement (FAI): preliminary results on comparison of standard diagnostic vs delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC). Osteoarthritis Cartilage (2009) 1.08
Disc assessment and visual field analysis in a hospital glaucoma population. Br J Ophthalmol (1982) 1.08
Anesthetic efficacy and heart rate effects of the intraosseous injection of 1.5% etidocaine (1:200,000 epinephrine) after an inferior alveolar nerve block. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 1.08
Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin (2009) 1.07
Anatomy of piriformis, obturator internus and obturator externus: implications for the posterior surgical approach to the hip. J Bone Joint Surg Br (2010) 1.06
Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry (2007) 1.06
Heterogeneity of Morquio disease. Clin Genet (1986) 1.05
Expression of the human chondrocyte phenotype in vitro. In Vitro Cell Dev Biol (1989) 1.04
Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol (2000) 1.04
Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol (2006) 1.04